News

(Bloomberg) -- After falling off their perch in the last few months of 2024, European healthcare stocks head into a new year facing the jeopardy of US politics and high-stakes trial results for new drugs.Most Read from BloombergNYPD Car Chases Are Becoming More Frequent — and More DangerousDakar’s Air Quality Plummets as Saharan Dust Descends on SenegalKey for investors will be clarity on American healthcare policy after president-elect Donald Trump’s nomination of health officials, including a

A new antibody from Merck would join a market teeming with new entries, but plenty of regulatory and financial uncertainty.

SINGAPORE (Reuters) -The dollar flirted with a two-year peak on Thursday after the Federal Reserve signalled a slower pace of rate cuts in 2025, while the yen slid after the Bank of Japan (BOJ) stood pat on rates and offered few clues on its monetary outlook. The BOJ kept interest rates steady earlier in the day, as expected, sending the yen down as much as 0.3%. The Japanese currency then extended losses to weaken past the 156 per dollar level for the first time in a month as BOJ Governor Kazuo Ueda spoke in a post-meeting press conference that kicked off at 0630 GMT.

The Dow hit a 10th straight day of losses, its worst streak since 1974, as stocks plummeted amid the outlook for fewer rate cuts in 2025.

Fintech firm Nukkleus saw its market cap jump from about $3 million to $125 million in just two days.

BofA said Expedia is its top internet value stock, hiking its price target to $221 amid improving US travel trends and a management shakeup under its new CEO.

Telsa's stock has soared along with CEO Elon Musk's visibility after Donald Trump's victory.